王佳丽,方全

• 1:中国医学科学院北京协和医学院北京协和医院心内科

摘要(Abstract)：

<正>近年来,随着导管消融技术的发展及其治疗心房颤动(房颤)的疗效优于抗心律失常药物的研究结果,国内外指南中均将导管消融术列为房颤的一线治疗方案~[1-3]。由于导管消融术在左心房内操作时间长,局部血栓形成和消融部位焦痂脱落等原因,围术期血栓栓塞及出血风险较高,如何平

关键词(KeyWords)： 新型口服抗凝药物;导管消融;心房颤动

Abstract:

Keywords:

基金项目(Foundation): 北京科委中国人房颤抗凝治疗最佳强度范围的比较效果研究(D11110700300000)

作者(Author): 王佳丽,方全

参考文献(References)：

• [1]Camm AJ,Lip GY,De Caterina R,et al.2012 focused update of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation.Developed with the special contribution of the European Heart Rhythm Association.Eur Heart J,2012,33(21):2719-2747.
• [2]January CT,Wann LS,Alpert JS,et al.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.J Am Coll Cardiol,2014,64(21):e1-e76.
• [3]中国医师协会心律学专业委员会心房颤动防治专家工作组,中华医学会心电生理和起搏分会.心房颤动:目前的认识和治疗建议—2015.中华心律失常学杂志,2015,19(5):321-384.
• [4]Di Biase L,Burkhardt JD,Santangeli P,et al.Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management:results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation(AF)Patients Undergoing Catheter Ablation(COMPARE)randomized trial.Circulation,2014,129(25):2638-2644.
• [5]Yeh CH,Hogg K,Weitz JI.Overview of the new oral anticoagulants:opportunities and challenges.Arterioscler Thromb Vasc Biol,2015,35(5):1056-1065.
• [6]Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med,2009,361(12):1139-1151.
• [7]Patel MR,Mahaffey KW,Garg J,et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med,2011,365(10):883-891.
• [8]Granger CB,Alexander JH,Mc Murray JJ,et al.Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med,2011,365(11):981-992.
• [9]Giugliano RP,Ruff CT,Braunwald E,et al.Edoxaban versus warfarin in patients with atrial fibrillation.N Engl J Med,2013,369(22):2093-2104.
• [10]Petersen P,Boysen G,Godtfredsen J,et al.Placebo-controlled,randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation.The Copenhagen AFASAK study.Lancet,1989,1(8631):175-179.
• [11]佟佳宾,施海峰,邹彤,等.高龄心房颤动患者导管消融围术期不同抗凝方案的对比观察.中国介入心脏病学杂志,2014,22(4):220-224.
• [12]Lakkireddy D,Reddy YM,Di Biase L,et al.Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation:results from a multicenter prospective registry.J Am Coll Cardiol,2012,59(13):1168-1174.
• [13]Bassiouny M,Saliba W,Rickard J,et al.Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.Circ Arrhythm Electrophysiol,2013,6(3):460-466.
• [14]Kim JS,She F,Jongnarangsin K,et al.Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation.Heart Rhythm,2013,10:483-489.
• [15]Nin T,Sairaku A,Yoshida Y,et al.A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation.Pacing Clin Electrophysiol,2013,36(2):172-179.
• [16]Bin Abdulhak AA,Khan AR,Tleyjeh IM,et al.Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation:a systematic review and meta-analysis.Europace,2013,15(10):1412-1420.
• [17]Providência R,Albenque JP,Combes S,et al.Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation:a systematic review and meta-analysis.Heart,2014,100(4):324-335.
• [18]Phan K,Wang N,Pison L,et al.Meta-analysis of dabigatran vs warfarin in patients undergoing catheter ablation for atrial fibrillation.Int J Cardiol,2015,189:199-203.
• [19]Steinberg BA,Hasselblad V,Atwater BD,et al.Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation:a meta-analysis of observational studies.J Interv Card Electrophysiol,2013,37(3):213-221.
• [20]Sardar P,Nairooz R,Chatterjee S,et al.Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation.Am J Cardiol,2014,113(7):1173-1177.
• [21]Lu D,Zhang Q,Liu Q,et al.Bleeding risks with novel oral anticoagulants during catheter ablation of atrial fibrillation:a systematic review and network meta-analysis.J Interv Card Electrophysiol,2015,44(2):105-111.
• [22]Nagao T,Inden Y,Yanagisawa S,et al.Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation.Heart Rhythm,2015,12(9):1972-1978.
• [23]Calkins H,Gerstenfeld EP,Schilling R,et al.RE-CIRCUIT study-randomized evaluation of Dabigatran etexilate compared to warfarin in pulmonary vein ablation:assessment of an uninterrupted periprocedural anticoagulation strategy.Am J Cardiol,2015,115(1):154-155.
• [24]Goya M,Nogami A,Hirao K,et al.Ablation perioperative dabigatran in use envisioning in Japan:The ABRIDGE-J Study Design.J Cardiol,2015.Epub ahead of print.
• [25]Lakkireddy D,Reddy YM,Di Biase L,et al.Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation:results from a multicenter prospective registry.J Am Coll Cardiol,2014,63(10):982-988.
• [26]Cappato R,Marchlinski F E,Hohnloser S H,et al.Uninterrupted rivaroxaban vs.uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.Eur Heart J,2015,36(28):1805-1811
• [27]Providência R,Marijon E,Albenque JP,et al.Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.Europace,2014,16(8):1137-1144.
• [28]Vamos M,Cappato R,Marchlinski FE,et al.Efficacy and safety of rivaroxaban compared with vitamin K antagonists for periprocedural anticoagulation in catheter ablation of atrial fibrillation:a systematic review and meta-analysis.Europace,2016.Epub ahead of print.
• [29]Nairooz R,Sardar P,Pino M,et al.Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.Int J Cardiol,2015,187:345-353.
• [30]Di Biase L,Lakkireddy D,Trivedi C,et al.Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation:Results from a multicenter study.Heart Rhythm,2015,12(6):1162-1168.
• [31]Nagao T,Inden Y,Shimano M,et al.Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.Pacing Clin Electrophysiol,2015,38(2):155-163.
• [32]Kuwahara T,Abe M,Yamaki M,et al.Apixaban versus warfarin for the prevention of periprocedural cerebral thromboembolism in atrial fibrillation ablation:multicenter prospective randomized study.J Cardiovasc Electrophysiol,2016,27(5):549-554.
• [33]Rillig A,Lin T,Plesman J,et al.Apixaban,rivaroxaban,and dabigatran in patients undergoing atrial fibrillation ablation.J Cardiovasc Electrophysiol,2016,27(2):147-153.
• [34]Hansen PS,Sanchez R,Walfridsson H.Safety of novel oral anticoagulants in catheter ablation of atrial fibrillation.Dan Med J,2016,63(2):A5186.
• [35]Gomez-Outes A,Suarez-Gea M L,Lecumberri R,et al.Directacting oral anticoagulants:pharmacology,indications,management,and future perspectives.Eur J Haematol,2015,95(5):389-404.
• [36]Nakamura K,Naito S,Sasaki T,et al.Silent cerebral ischemic lesions after catheter ablation of atrial fibrillation in patients on 5types of periprocedural oral anticoagulation-predictors of diffusion-weighted imaging-positive lesions and follow-up magnetic resonance imaging.Circ J,2016,80(4):870-877.